Comparison of antiemetic efficacy between single and repeat treatment with dexamethasone in patients receiving carboplatin-based combination chemotherapy

Hitoshi Kawazoe, Y. Motoki, Y. Takechi, Y. Shishino, K. Ido, K. Suemaru, H. Araki

Research output: Contribution to journalArticle

Abstract

A retrospective study was carried out to compare the preventive effects of single and repeat treatment with dexamethasone (DEX) on delayed nausea and emesis in patients who had received carboplatin (CBDCA)-based combination chemotherapy. Sixty-four patients were evaluated. Efficacy was assessed using the nausea and emesis score, food intake score and the requirement for antiemetic medication. These forward scores were categorized as three-grade during the first 5 days after chemotherapy. Acute nausea and emesis were well controlled in both groups on day 1. Mean values of the nausea and emesis score on day 3 evening and the food intake score on day 4 morning in the repeat-treatment group was 1.31 ± 0.93 and 3.46 ± 1.03, respectively, which were significantly better when compared with the singletreatment group (2.00 ± 1.52; P = 0.028 and 2.79 ± 1.12; P = 0.018, respectively). Multivariate logistic regression analysis revealed that less frequent dispensing of antiemetic medication was significantly associated with the repeat-treatment group (adjusted odds ratio, 0.153; 95% confidence interval, 0.026-0.734; P = 0.018). These results suggest that repeat-dose DEX may be more effective than single-dose DEX for the prevention of delayed nausea and emesis after CBDCA-based combination chemotherapy.

Original languageEnglish
Pages (from-to)499-505
Number of pages7
JournalMethods and Findings in Experimental and Clinical Pharmacology
Volume32
Issue number7
DOIs
Publication statusPublished - 2010 Dec 1
Externally publishedYes

Fingerprint

Antiemetics
Carboplatin
Combination Drug Therapy
Nausea
Dexamethasone
Vomiting
Eating
Therapeutics
Retrospective Studies
Logistic Models
Odds Ratio
Regression Analysis
Confidence Intervals
Drug Therapy

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Comparison of antiemetic efficacy between single and repeat treatment with dexamethasone in patients receiving carboplatin-based combination chemotherapy. / Kawazoe, Hitoshi; Motoki, Y.; Takechi, Y.; Shishino, Y.; Ido, K.; Suemaru, K.; Araki, H.

In: Methods and Findings in Experimental and Clinical Pharmacology, Vol. 32, No. 7, 01.12.2010, p. 499-505.

Research output: Contribution to journalArticle

@article{c2a6bef383bd451ab9999a4dc608b1b3,
title = "Comparison of antiemetic efficacy between single and repeat treatment with dexamethasone in patients receiving carboplatin-based combination chemotherapy",
abstract = "A retrospective study was carried out to compare the preventive effects of single and repeat treatment with dexamethasone (DEX) on delayed nausea and emesis in patients who had received carboplatin (CBDCA)-based combination chemotherapy. Sixty-four patients were evaluated. Efficacy was assessed using the nausea and emesis score, food intake score and the requirement for antiemetic medication. These forward scores were categorized as three-grade during the first 5 days after chemotherapy. Acute nausea and emesis were well controlled in both groups on day 1. Mean values of the nausea and emesis score on day 3 evening and the food intake score on day 4 morning in the repeat-treatment group was 1.31 ± 0.93 and 3.46 ± 1.03, respectively, which were significantly better when compared with the singletreatment group (2.00 ± 1.52; P = 0.028 and 2.79 ± 1.12; P = 0.018, respectively). Multivariate logistic regression analysis revealed that less frequent dispensing of antiemetic medication was significantly associated with the repeat-treatment group (adjusted odds ratio, 0.153; 95{\%} confidence interval, 0.026-0.734; P = 0.018). These results suggest that repeat-dose DEX may be more effective than single-dose DEX for the prevention of delayed nausea and emesis after CBDCA-based combination chemotherapy.",
author = "Hitoshi Kawazoe and Y. Motoki and Y. Takechi and Y. Shishino and K. Ido and K. Suemaru and H. Araki",
year = "2010",
month = "12",
day = "1",
doi = "10.1358/mf.2010.32.7.1501438",
language = "English",
volume = "32",
pages = "499--505",
journal = "Methods and Findings in Experimental and Clinical Pharmacology",
issn = "0379-0355",
publisher = "Prous Science",
number = "7",

}

TY - JOUR

T1 - Comparison of antiemetic efficacy between single and repeat treatment with dexamethasone in patients receiving carboplatin-based combination chemotherapy

AU - Kawazoe, Hitoshi

AU - Motoki, Y.

AU - Takechi, Y.

AU - Shishino, Y.

AU - Ido, K.

AU - Suemaru, K.

AU - Araki, H.

PY - 2010/12/1

Y1 - 2010/12/1

N2 - A retrospective study was carried out to compare the preventive effects of single and repeat treatment with dexamethasone (DEX) on delayed nausea and emesis in patients who had received carboplatin (CBDCA)-based combination chemotherapy. Sixty-four patients were evaluated. Efficacy was assessed using the nausea and emesis score, food intake score and the requirement for antiemetic medication. These forward scores were categorized as three-grade during the first 5 days after chemotherapy. Acute nausea and emesis were well controlled in both groups on day 1. Mean values of the nausea and emesis score on day 3 evening and the food intake score on day 4 morning in the repeat-treatment group was 1.31 ± 0.93 and 3.46 ± 1.03, respectively, which were significantly better when compared with the singletreatment group (2.00 ± 1.52; P = 0.028 and 2.79 ± 1.12; P = 0.018, respectively). Multivariate logistic regression analysis revealed that less frequent dispensing of antiemetic medication was significantly associated with the repeat-treatment group (adjusted odds ratio, 0.153; 95% confidence interval, 0.026-0.734; P = 0.018). These results suggest that repeat-dose DEX may be more effective than single-dose DEX for the prevention of delayed nausea and emesis after CBDCA-based combination chemotherapy.

AB - A retrospective study was carried out to compare the preventive effects of single and repeat treatment with dexamethasone (DEX) on delayed nausea and emesis in patients who had received carboplatin (CBDCA)-based combination chemotherapy. Sixty-four patients were evaluated. Efficacy was assessed using the nausea and emesis score, food intake score and the requirement for antiemetic medication. These forward scores were categorized as three-grade during the first 5 days after chemotherapy. Acute nausea and emesis were well controlled in both groups on day 1. Mean values of the nausea and emesis score on day 3 evening and the food intake score on day 4 morning in the repeat-treatment group was 1.31 ± 0.93 and 3.46 ± 1.03, respectively, which were significantly better when compared with the singletreatment group (2.00 ± 1.52; P = 0.028 and 2.79 ± 1.12; P = 0.018, respectively). Multivariate logistic regression analysis revealed that less frequent dispensing of antiemetic medication was significantly associated with the repeat-treatment group (adjusted odds ratio, 0.153; 95% confidence interval, 0.026-0.734; P = 0.018). These results suggest that repeat-dose DEX may be more effective than single-dose DEX for the prevention of delayed nausea and emesis after CBDCA-based combination chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=79952479904&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952479904&partnerID=8YFLogxK

U2 - 10.1358/mf.2010.32.7.1501438

DO - 10.1358/mf.2010.32.7.1501438

M3 - Article

VL - 32

SP - 499

EP - 505

JO - Methods and Findings in Experimental and Clinical Pharmacology

JF - Methods and Findings in Experimental and Clinical Pharmacology

SN - 0379-0355

IS - 7

ER -